Substance + claimed effects

Small intestinal bacterial overgrowth (SIBO) is the proliferation of bacteria — and, separately, methane-producing archaea (intestinal methanogen overgrowth, IMO) — in the small bowel above thresholds normally seen in healthy controls. The historical aspirate cut-off was ≥10⁵ CFU/mL of jejunal fluid; the current North American Consensus and ACG guideline use >10³ CFU/mL of coliform bacteria Pimentel et al. 2020. Claimed effects span GI symptoms (bloating, flatulence, abdominal pain, altered stool form), nutrient malabsorption (B₁₂, iron, fat-soluble vitamins A/D/E/K via bile-salt deconjugation), and contribution to IBS — particularly bloating-dominant and constipation-dominant subtypes. This entry covers SIBO end-to-end as a defined clinical condition: who actually has it, how to test, how to treat, the diagnostic-accuracy and over-diagnosis controversy, and the boundary between evidence-based GI care and the wellness-industry version that has grown up around an unreliable test.

Evidence by addressing question

Mechanism

The small intestine maintains low bacterial density (typically <10⁴ CFU/mL) by three defences: gastric acid (kills swallowed organisms), the migrating motor complex (MMC, the fasting-state sweep that flushes the small bowel every ~90 minutes), and the ileocecal valve (stops colonic reflux). Breach any of the three and proximal colonization rises. Established risk factors map cleanly onto these defences Pimentel et al. 2020 Quigley et al. 2020:

• Acid suppression. PPI use raises SIBO prevalence — meta-analysis of 11 studies (n=3,134) shows OR 1.71 (95% CI 1.20–2.43) when SIBO is defined by aspirate or glucose breath test, with stronger association in higher-quality studies Lo & Chan 2013.
• Dysmotility. Scleroderma, diabetic autonomic neuropathy, post-vagotomy states, opioid use, idiopathic gastroparesis — anything that disables the MMC.
• Anatomic. Surgical blind loops, strictures, fistulae, Roux-en-Y, resected ileocecal valve.

Symptoms have two mechanical routes. (1) Bacterial fermentation of dietary carbohydrates in the proximal bowel produces hydrogen and CO₂ in the gas phase — the bloating. (2) Bacterial deconjugation of bile acids impairs micelle formation, causing fat maldigestion (steatorrhea) and secondary fat-soluble vitamin loss; bacterial uptake of B₁₂ in the lumen produces a macrocytic-anemia signal. Mucosal damage (villous blunting from enteroadherent organisms) compounds malabsorption. Methane gas itself slows transit in a dose-dependent fashion in animal models — methane infusion into the small intestine of dogs reduced transit by ~59% Pimentel et al. 2006, supplying a mechanistic basis for the IMO–constipation link.

Evidence

The case that SIBO is a real clinical entity in defined populations is uncontested: bacterial overgrowth on aspirate culture in patients with scleroderma, post-surgical blind loops, or severe gastroparesis correlates with steatorrhea, malabsorption, and symptom response to antibiotic decontamination. The contested case is the much larger one of breath-test-positive symptomatic patients without anatomic or motility predisposition, who now make up the majority of SIBO diagnoses Quigley et al. 2020.

Breath-test performance against the aspirate reference is poor. A 2020 meta-analysis of 14 studies (n=1,777) found pooled sensitivity 0.42 (95% CI 0.39–0.45) and specificity 0.91 (95% CI 0.89–0.93) for lactulose breath test; glucose breath test pooled sensitivity 0.55 (95% CI 0.51–0.59) and specificity 0.83 (95% CI 0.80–0.86) Losurdo et al. 2020. Lactulose's higher false-positive rate reflects rapid orocecal transit producing an early "second peak" that is colonic fermentation, not small-bowel overgrowth. The North American Consensus partly addresses this by setting the threshold at ≥20 ppm rise in H₂ from baseline by 90 minutes, and ≥10 ppm CH₄ at any time Rezaie et al. 2017, but real-world inter-rater agreement and substrate selection remain inconsistent.

Treatment evidence is strongest for rifaximin. Gatta & Scarpignato's meta-analysis pooled 32 studies (n=1,331) and found ITT eradication 70.8% (95% CI 61.4–78.2) and PP eradication 72.9% (95% CI 65.5–79.8); 67.7% of eradicated patients had symptom improvement; adverse-event rate 4.6% with treatment discontinuation 0.47% Gatta & Scarpignato 2017. A 2021 update reported lower pooled eradication (ITT 59%) with dose-dependence — 1,600 mg/day > 1,200 mg/day > 800 mg/day. For IBS-without-constipation (a SIBO-overlap population), the TARGET-1/2 phase-3 RCTs (n=1,260) showed rifaximin 550 mg TID × 14 days produced adequate global IBS relief in 40.7% vs 31.7% placebo (p<0.001), with effect sustained 10 weeks post-treatment Pimentel et al. 2011.

For methane-positive (IMO) patients, monotherapy is less effective. Low et al.'s prospective comparison gave rifaximin 400 mg + neomycin 500 mg BID × 10 days vs either alone; the combination eradicated methane in 87% vs ~30% for rifaximin alone Low et al. 2010. Elemental-diet treatment — 14 days on a hypoallergenic free-amino-acid formula — normalized lactulose breath tests in 80% of patients in Pimentel's original trial (n=124) Pimentel et al. 2004, replicated in more recent open-label work at ~73% normalization. An open-label comparison of an herbal antimicrobial protocol (oregano, berberine, allicin) vs rifaximin in 104 patients showed equivalent breath-test normalization (46% herbal vs 34% rifaximin) Chedid et al. 2014, though without blinding or placebo control.

Recurrence is the dominant treatment-side problem. Lauritano et al. followed 80 rifaximin-eradicated patients and documented breath-test recurrence in 12.6% at 3 months, 27.5% at 6 months, and 43.7% at 9 months Lauritano et al. 2008. Higher in patients ≥65, post-cholecystectomy, or on chronic PPI. No RCT establishes that any specific prokinetic prevents SIBO recurrence in this setting — the prokinetic-post-eradication paradigm rests on expert opinion and small uncontrolled series.

Protocol

The mainstream protocol assembled from ACG and AGA guidance:

• Pre-test the indication. Symptoms (bloating, distention, gas, altered bowels) + a plausible risk factor (prior abdominal surgery, scleroderma, gastroparesis, chronic PPI, severe IBS). Testing low-pretest-probability patients amplifies the false-positive problem given specificity ≤91% Losurdo et al. 2020.
• Test. Glucose 75 g or lactulose 10 g breath test with H₂ and CH₄ sampling every 15 min for 90–120 min. Glucose is more specific (proximal-jejunal pickup, less colonic contamination); lactulose covers more distal bowel but generates more false positives. ≥20 ppm H₂ rise from baseline by 90 min or ≥10 ppm CH₄ any time = positive Rezaie et al. 2017. Three-gas testing adding H₂S (Trio-smart, FDA-registered) extends coverage to sulfide-producing overgrowth (diarrhea-correlated) — emerging, not yet in formal guidelines.
• Treat hydrogen-positive. Rifaximin 550 mg PO TID × 14 days (the IBS-D and ACG-suggested dose). Eradication ~60–70%, symptom relief ~60% of eradicated Gatta & Scarpignato 2017.
• Treat methane-positive (IMO). Rifaximin 550 mg TID + neomycin 500 mg BID × 14 days, or rifaximin + metronidazole 250 mg TID. Methanogens resist rifaximin monotherapy Low et al. 2010.
• Retreat on recurrence. TARGET-3 established that re-treatment with the same rifaximin regimen at relapse is effective; up to 2 retreatments studied.
• Adjunctive. Address root cause (deprescribe PPI if possible, treat dysmotility), consider low-FODMAP transitionally, address coexisting micronutrient deficiencies (B₁₂, iron, fat-soluble vitamins).

Contraindications

Rifaximin is non-absorbable (<0.4% systemic bioavailability) and FDA-pregnancy category C — generally avoided in pregnancy because of limited human data, though plausibly safer than systemic antibiotics. Neomycin is ototoxic and nephrotoxic with chronic use; the 10–14-day SIBO dose is generally tolerated but contraindicated in pre-existing renal impairment or hearing loss. Metronidazole interacts with alcohol (disulfiram-like reaction) and carries peripheral-neuropathy risk on repeated courses. Breath testing itself is benign; the substrate volume (250 mL water + sugar) can transiently exacerbate symptoms.

Misconceptions

• "A positive breath test means SIBO." Pooled sensitivity 0.42–0.55 and specificity 0.83–0.91 against aspirate Losurdo et al. 2020. In a 30%-prevalence population the positive predictive value is roughly 70%; in a 10%-prevalence population (low-pretest IBS without dysmotility), PPV falls to ~40%. The test is most useful at narrowing in a pre-selected population, not as a screen.
• "SIBO is the cause of my chronic fatigue / brain fog / rosacea / autoimmune disease." Outside GI symptoms and malabsorption, evidence is sparse to absent. The AGA Clinical Practice Update specifically warns against the breadth of conditions to which SIBO is attributed in lay press Quigley et al. 2020.
• "Eradication = cure." Recurrence is ~44% by 9 months without root-cause correction Lauritano et al. 2008.
• "Probiotics treat SIBO." Mixed evidence; a meta-analysis suggested ~53% eradication signal, but heterogeneity is severe and trial quality low. AGA does not recommend.
• "Lactulose and glucose are interchangeable." Lactulose breath test produces ~10x the positivity rate of glucose in IBS populations because rapid transit creates a colonic-fermentation signal mimicking SIBO.

Audience

Populations where SIBO is genuinely common and worth aggressive workup: systemic sclerosis (~38% prevalence in symptomatic patients Marie et al. 2009), post-Roux-en-Y bariatric surgery, post-bowel-resection with anatomic alterations, severe gastroparesis (diabetic or idiopathic), advanced cirrhosis with portal hypertension, chronic-opioid users with persistent GI symptoms. Populations where SIBO labels are overused: young adults with bloating and no risk factors, patients who have already cycled through "SIBO protocols" without symptom durability, anyone whose breath-test diagnosis came from a direct-to-consumer kit interpreted without clinical context.

Alternatives

For the typical bloating/IBS-overlap patient, well-evidenced alternatives that often resolve the same complaint without invoking SIBO: low-FODMAP diet (NICE/BDA-supported, ~50–70% IBS symptom response), neuromodulators (low-dose TCAs for visceral hypersensitivity), peppermint oil enteric capsules (Cochrane-positive for IBS pain), CBT/gut-directed hypnotherapy. For methane-positive constipation specifically: prokinetics (prucalopride 1–2 mg daily, low-dose erythromycin) and osmotic laxatives may produce comparable symptom benefit without antibiotic exposure.

Failure-modes

• Treating a false-positive breath test with antibiotics. Patient gets transient placebo + non-specific gut-microbiome effect of rifaximin, symptoms relapse, cycle repeats.
• Not addressing root cause. PPI never deprescribed, motility issue never named, scleroderma never recognized.
• Missing IMO. Hydrogen-only test in a methane producer reports "negative" — the patient stays constipated.
• Endless cycling. Patients on their 4th or 5th SIBO protocol with no objective improvement are signaling that SIBO is probably not the unifying diagnosis, regardless of breath-test results.

Practicalities

Breath test costs $150–$400 cash; in-office $200–$500; CPT 91065 is increasingly covered by commercial insurance and Medicare with documented medical necessity but many plans still call it "experimental." Rifaximin (Xifaxan 550 mg) has no US generic before 2029 — retail ~$2,200–$3,000 per 14-day course; insurance coverage for the off-label SIBO indication often requires prior authorization with letter of medical necessity. Generic neomycin and metronidazole are inexpensive. Three-gas testing adds $50–$100. Elemental diet formulas (Vivonex, custom-compounded) run ~$200–$400 for a 14-day course and require strict adherence — most patients tolerate poorly.

Stakes

Untreated SIBO in a true high-risk patient (scleroderma, post-surgical blind loop) produces progressive malabsorption: weight loss, B₁₂-deficient macrocytic anemia, fat-soluble vitamin deficits, osteopenia from chronic vitamin D and calcium loss, fatigue, peripheral neuropathy from B₁₂. In the more common breath-test-positive IBS-overlap patient, the "stakes" are mostly continued bloating/discomfort and the iatrogenic cost of repeated antibiotic exposure and unproven supplement regimens.

Payoff

In responders: post-treatment bloating typically resolves within 1–2 weeks, with bowel-habit normalization tracking close behind. ~60% of eradicated patients report sustained symptom improvement at 4–10 weeks Gatta & Scarpignato 2017 Pimentel et al. 2011. In high-risk patients (scleroderma), aggressive cycling treatment can restore weight and nutritional status. Durability is the catch: ~44% recur by 9 months without root-cause work Lauritano et al. 2008.

Out-of-scope

Adjacent topics worth signposting in the article's closing pointers: IBS, low-FODMAP eating, PPI deprescribing, fecal microbiota transplant (no evidence-base in SIBO), small intestinal fungal overgrowth (SIFO — emerging entity, even less standardized).

The credibility range

Optimist case

SIBO is a real, common, under-recognized condition. The MMC story is mechanistically airtight; the populations where aspirate-confirmed overgrowth correlates with steatorrhea and B₁₂ deficiency leave no doubt the entity exists. Breath testing has known imperfections but is the only practical noninvasive option; the North American Consensus standardized thresholds and substrate, and three-gas testing is closing the H₂S blind spot. Rifaximin has level-1 RCT evidence in IBS-D (TARGET-1/2; n=1,260) with a clean safety profile Pimentel et al. 2011. The IMO category — with its own pathophysiology and combination-therapy response — is a refinement, not a retreat. The under-diagnosis story is at least as plausible as the over-diagnosis story: many bloated patients are dismissed as "IBS" with no workup, miss a treatable root cause, and cycle through dietary restriction instead of resolving the underlying overgrowth.

Skeptic case

Breath testing has poor sensitivity (≤55%) and imperfect specificity (≤91%) against the aspirate gold standard Losurdo et al. 2020, so its widespread use in low-pretest-probability populations produces a steady stream of false positives — particularly with lactulose, which generates ~10x the positivity rate of glucose because it reaches the colon. The AGA Clinical Practice Update by Quigley, Murray & Pimentel notes that the entity's definition "lacks precision and consistency" and that symptoms are "weakly predictive at best" without obvious predisposing factors Quigley et al. 2020. The rifaximin signal in IBS may be a non-specific microbiome-modulation effect rather than SIBO eradication per se — the placebo-control delta in TARGET (40.7% vs 31.7%) is ~9 percentage points, real but modest, and most patients eventually relapse Pimentel et al. 2011. Commercial incentives are non-trivial: Mark Pimentel — author of the ACG guideline, the North American Consensus, the elemental-diet trial, the IMO terminology, and Trio-smart's research lead — has consulted for or received support from Salix (manufactures rifaximin) and Gemelli Biotech (sells Trio-smart). The lay-press/wellness-industry version of SIBO blames it for fatigue, brain fog, rosacea, autoimmunity, and dozens of other complaints with essentially no controlled evidence.

Author's call

Both true and over-diagnosed. The entity is well-defined and treatable in clear high-risk groups (scleroderma, post-surgical, severe dysmotility, advanced cirrhosis); breath testing in this enriched population is genuinely useful and rifaximin works. Outside that, the test's specificity is too low to drive antibiotic decisions in the population that drives most SIBO diagnoses — bloated, otherwise-well IBS patients with no risk factor. The article should treat SIBO as a real clinical condition with a contested diagnostic infrastructure and lean the reader toward GI specialist evaluation (not a wellness clinic or DTC kit), risk-factor-stratified testing, and skepticism of long-running personal "SIBO protocols" that never durably resolve. evidence ~3 (mechanism solid, RCTs exist but specificity issues meaningful); controversy ~3–4 (active debate, foundational disagreement on test interpretation and over-diagnosis bounds).

Stakeholder + incentive map

• Commercial: Salix Pharmaceuticals (rifaximin; brand Xifaxan; ~$1.5B/year US revenue at peak). Gemelli Biotech (Trio-smart breath test). Cedars-Sinai (patent licensing on lactulose breath-test methodology).
• Academic: Mark Pimentel and the Cedars-Sinai MAST program — productive research output, also commercial entanglement disclosed in every guideline (relevant to weighting the IMO/Trio-smart pipeline).
• Professional bodies: ACG (broadly endorses breath testing and rifaximin Pimentel et al. 2020) vs AGA Clinical Practice Update (more skeptical posture, same primary author Quigley et al. 2020). Rome Foundation runs in the IBS lane and is broadly more cautious on the SIBO–IBS overlap claim.
• Community / wellness: functional-medicine practitioners and DTC labs run high-volume SIBO testing; "SIBO diet" content saturates the wellness internet; herbal-antimicrobial protocols sell well; recurrence-and-retest economics keep patients in long-running relationships.
• Counter-incentive: antimicrobial-stewardship voices, generalist GI practitioners skeptical of breath-test-driven diagnoses, primary-care clinicians who see SIBO labels arrive from wellness clinics and have to manage the aftermath.

Population variability

• High-risk groups (high pretest probability, test pays off): systemic sclerosis (38% in symptomatic Marie et al. 2009), post-bariatric (Roux-en-Y), post-bowel-resection, severe gastroparesis (diabetic or idiopathic), advanced cirrhosis, chronic-opioid users with persistent GI symptoms, the elderly on long-term PPIs.
• Intermediate: IBS with constipation predominance — IMO is enriched in IBS-C and methane testing with combination therapy may genuinely help.
• Low-yield: young otherwise-well adults with bloating, no risk factor, breath-test positive — most likely false positive or a clinically meaningless overgrowth that responds to dietary modification alone.
• Age/sex: Female predominance in IBS-overlap presentations; older age and post-cholecystectomy state both increase recurrence risk after eradication.

Knowledge gaps

• Whether breath-test-positive without aspirate-confirmation is the same disease as aspirate-positive SIBO. Likely a spectrum, but the test-positive-without-risk-factor population is poorly characterized.
• Whether H₂S-positive SIBO (intestinal sulfide overproduction) is a distinct treatable entity or a research artifact — early Trio-smart data are promising but no RCT base.
• No RCT confirms that any specific prokinetic prevents SIBO recurrence; the post-eradication paradigm is expert opinion.
• No head-to-head of rifaximin vs herbal protocols beyond the single Chedid open-label trial.
• What "SIBO" actually means at the microbiome level — culture-independent sequencing finds that the small-bowel microbiome of symptomatic vs asymptomatic individuals overlaps heavily, suggesting overgrowth is one phenotype of broader small-bowel dysbiosis rather than a discrete syndrome.
• The evidence that durably resolving SIBO improves any non-GI outcome (fatigue, mood, "brain fog") is essentially absent despite the centrality of these claims in lay discussion.

Scope and framing

The brief named four consequence areas: GI symptoms, nutrient absorption, diagnostic accuracy, and the evidence-based vs over-diagnosed boundary. All four are covered. The article centers on the diagnostic-accuracy and over-diagnosis angle because that's where the catalogue's reader is most likely to be making a real decision (or being talked into a wrong one) — most people encountering "SIBO" first do so through wellness channels rather than a gastroenterologist's office.

Action / cadence call

Picked know rather than test or decide. This entry's primary job is condition literacy — sorting wellness mythology from the real entity. The actual decision to test/treat falls out of recognizing whether you're in the high-risk-factor group, which is a downstream consequence of knowing. Cadence as-needed because workup is symptom-and-risk-triggered, not periodic.

Dimension scoring

• Energy and mood scored 0. Considered scoring both at 1 (downstream of resolved malabsorption / GI symptom relief), but the spec requires non-zero dimensions to get a real paragraph in the body. The article's tightest version treats GI symptom relief as the only direct consequence (health_short_term: 3) and explicitly debunks the wellness-internet claim that SIBO is the unifying cause of fatigue/brain fog/mood symptoms. Scoring energy or mood non-zero would have softened that posture against the lay-press over-attribution.
• Evidence 3, controversy 4. The split is the point — mechanism and treatment have decent data, the diagnostic test that gates everything does not, and major guideline bodies (ACG vs AGA Clinical Practice Update) disagree on how heavily to lean on it. Commercial entanglements (Pimentel / Salix / Gemelli) belong in the controversy score, not the evidence score.
• Cost burden 3. Driven almost entirely by rifaximin's US brand-only status (no generic until 2029). If insurance covers the IBS-D indication, real cost can drop to a 2; without coverage, easily a 3 or even 4.

Excluded

• SIFO (small intestinal fungal overgrowth). Adjacent, less standardized; mentioned in dossier out-of-scope but not in the article. Separate-entry candidate when the evidence base matures.
• Detailed mechanism on hydrogen sulfide. Trio-smart is mentioned in passing; full H₂S/ISO story is still in research-translation phase. Worth revisiting in 2–3 years.
• Specific herbal-antimicrobial protocols. Chedid 2014 is cited in dossier but not the article — one open-label trial isn't enough to anchor reader-facing prose, and getting into oregano/berberine/allicin specifics risks the wellness-clinic voice the article is trying to push back against.
• Detailed FMT and probiotic protocols. Probiotics get a one-line dismissal in misconceptions; FMT is absent because the evidence base in SIBO specifically is essentially nil.

Future links

Entries this one should cross-link to as they land: ibs, low-fodmap, ppi-deprescribing, gastroparesis, celiac-disease. All flagged in out-of-scope section. methane-imo could become its own entry if the field's IMO-as-separate-syndrome direction holds.

Conflict-of-interest note for reviewer

Most of the SIBO literature this entry rests on shares an author (Mark Pimentel of Cedars-Sinai) with significant commercial disclosures to Salix (rifaximin manufacturer) and Gemelli Biotech (Trio-smart test). The article is honest about this in dossier and reflects it in the controversy score; reviewer should sanity-check that the article's framing isn't unwittingly amplifying the commercial-pipeline view. The AGA Clinical Practice Update Quigley et al. 2020 (also Pimentel-authored, but more skeptical in tone) is the counterweight cited throughout.

Tone choices

The dek and headline lean harder into the "real condition, fake test" framing than a neutral textbook would. Defensible because the catalogue's reader is far more likely to encounter SIBO over-diagnosis than under-diagnosis — the priors run that direction. A reader in a true high-risk group (scleroderma, post-bariatric) gets a clear signal in the audience section that the framing flips for them.